Insmed, Inc. $INSM Stake Increased by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP boosted its stake in Insmed, Inc. (NASDAQ:INSM) by 45.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 294,047 shares of the biopharmaceutical company’s stock after acquiring an additional 91,453 shares during the period. Insmed accounts for 0.2% of Brevan Howard Capital Management LP’s portfolio, making the stock its 24th largest position. Brevan Howard Capital Management LP owned approximately 0.14% of Insmed worth $42,346,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the stock. Kingsview Wealth Management LLC increased its position in shares of Insmed by 2.7% in the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 60 shares during the last quarter. Choreo LLC grew its stake in Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 65 shares in the last quarter. Spire Wealth Management increased its holdings in Insmed by 11.5% in the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 80 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in Insmed by 59.6% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 81 shares during the last quarter. Finally, Moody Aldrich Partners LLC raised its stake in Insmed by 2.4% during the third quarter. Moody Aldrich Partners LLC now owns 5,551 shares of the biopharmaceutical company’s stock valued at $799,000 after buying an additional 132 shares in the last quarter.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction on Monday, January 12th. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00. Following the transaction, the chief executive officer directly owned 306,891 shares in the company, valued at $51,864,579. The trade was a 5.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total value of $15,293,208.00. Following the sale, the insider directly owned 41,754 shares in the company, valued at $7,315,300.80. This trade represents a 67.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 189,651 shares of company stock worth $31,784,545. 3.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

INSM has been the topic of a number of research analyst reports. Jefferies Financial Group set a $269.00 target price on Insmed in a report on Wednesday, December 10th. Bank of America set a $203.00 price objective on Insmed in a research note on Thursday, December 18th. Roth Mkm raised shares of Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Mizuho lowered their target price on shares of Insmed from $211.00 to $204.00 and set an “outperform” rating for the company in a research note on Tuesday, February 24th. Finally, Citigroup reissued an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $207.52.

Insmed Price Performance

Shares of NASDAQ INSM opened at $139.50 on Friday. The firm’s 50-day simple moving average is $155.18 and its 200 day simple moving average is $165.94. The stock has a market cap of $30.07 billion, a P/E ratio of -21.76 and a beta of 1.13. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The company had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm’s quarterly revenue was up 152.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.32) earnings per share. Equities analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.